HERVolution Therapeutics Strengthens Advisory Board as IPT-001 Nears First-in-Human Trials

According to a recent LinkedIn post from HERVolution Therapeutics, the company is adding Dr. László B. Tankó to its Scientific Advisory Board. The post notes his prior role as CMO at obesity drug startup Six Peaks Bio, which was acquired by AstraZeneca in late 2025, and his 25-plus years of clinical leadership at Novartis, Bayer, and Ferring.

The post suggests that Dr. Tankó’s experience will support advancement of HERVolution’s lead program, IPT-001, toward first-in-human trials in metabolic disease later this year. It describes IPT-001 as a potentially first-in-class immunotherapy using a redesigned HERV-K antigen that aims to stimulate senolytic immune responses and could address a range of aging-related diseases.

For investors, the appointment signals an attempt to strengthen clinical and regulatory strategy ahead of a key inflection point as the company moves into human studies. If IPT-001 progresses as described, HERVolution could position itself within emerging cardiometabolic and aging-related therapeutics, though outcomes will depend on safety, efficacy, and competitive dynamics in metabolic and senescence-targeting drug development.